Madrigal Pharmaceuticals agreed to acquire six preclinical siRNA candidates from Ribo Life Science and Ribocure in a transaction valued at up to $4.4 billion tied to milestones. The acquisition adds oligonucleotide approaches to Madrigal’s metabolic dysfunction‑associated steatohepatitis (MASH) strategy and complements the company’s launched therapy, Rezdiffra (resmetirom). Ribo’s siRNA portfolio targets pathways implicated in fatty liver disease and other metabolic targets; Madrigal said the deal accelerates its pipeline diversification into RNA interference therapeutics. Financial terms include up‑front and milestone components, reflecting the value of preclinical RNAi assets capable of addressing core drivers of MASH. The deal spotlights ongoing consolidation as metabolic disease companies pursue multi‑modality portfolios to address complex chronic liver disease.